Skip to main content
. 2018 Oct 16;13(10):e0204914. doi: 10.1371/journal.pone.0204914

Table 2. Complications after HSCT.

Complications of HSCT Total patients: n (%) Allogeneic HSCT: n (%) Autologous HSCT: n (%) p–value
229 (100) 126 (100) 103 (100)
Complications
yes 170 (74.2) 112 (88.9) 58 (56.3)
no 59 (25.8) 14 (11.1) 45 (43.7)
Infections
Viral reactivation 36 (16.2) 33 (26.2) 3 (2.9) < .001 Chi2 *
chronic 4 (1.7) 4 (3.2) 0 (0,0) < .001 Chi2
transient 32 (13.5) 28 (22.3) 4 (3.8)
Severe bacterial infection/Sepsis 12 (5,2) 11 (8,7) 1 (1,0) .014 Chi2 *
Severe fungal infection 4 (1,7%) 4 (3,2) 0 (0,0) .129Chi
Severe mucosal ulcerations 7 (3.1) 6 (4.8) 1 (1,0) .133 FE
CNS disorders 8 (3,4) 8 (6,3) 0 (0.0) .009 FE *
Cardio-vascular complications
Cardiomyopathy 13 (5.7) 10 (7.3) 3 (2.9) .151 Chi2
ECG abnormalities 25 (10.9) 13 (10.3) 12 (11.6) .734 FE
Hyper—/ Hypotension 24 (10.5) 21 (16.7) 3 (2.9) < .001 FE *
Thrombosis / Embolism 29 (12.7) 24 (19.0) 5 (4.9) .001 Chi2 *
Pulmonary complications
Acute respiratory insufficiency 9 (3.9) 9 (7.1) 0 (0.0) .005 FE *
Impaired pulmonary function 55 (24.0) 37 (29.4) 18 (17.5) .043 Chi2 *
Renal insufficiency 16 (7.0) 11 (8.7) 5 (4.9) .252 Chi2
Transplant rejection 2 (0.9) 2 (1.6) 0 (0.0) .503 FE
Secondary malignancies 1 (0.4%) 1 (0.8) 0 (0.0) 1.000 FE
Abnormal audiogram 26 (11.4) 12 (9.5) 14 (13.6) .611 Chi2
Endocrine disorders
Total number 116 (50.7) 70 (55.6) 46 (44.7) .112 Chi2
Growth 33 (14.4) 14 (11.1) 19 (18.4) .132 Chi2 *
Thyroid 22 (9.6) 12 (9.5) 10 (9.7) 1.000 FE
Gonads 85 (38.4) 54 (42.9) 31 (30.1) .055 Chi2
Psychosocial problems 18 (7.8) 14 (11.1) 4 (3.9) .043 Chi2

Table 2 shows complications during the course of HSCT. Comparison of allogeneic and autologous HSCT patients with p-values and statistical tests used.

*Calculation of the p-value stating used tests: Chi2 = Chi-square-Test; FE = Fisher’s exact test. CI 95%; P≤0.05. * Significant at the 0.05 probability level.